Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalenceKoert Ritmeijer
Public Health Department, Medecins Sans Frontieres, Amsterdam, The Netherlands
Clin Infect Dis 53:e152-8. 2011
....
Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasisKoert Ritmeijer
Medecins Sans Frontieres Holland, Amsterdam, The Netherlands
Am J Trop Med Hyg 74:76-80. 2006
..Further diagnostic work-up of dipstick-negative patients with clinically suspected VL is important. The ease and convenience of the dipstick test will allow decentralization and improved access to care in disease-endemic areas in Sudan...
- A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection
Koert Ritmeijer
Medecins Sans Frontieres Holland, Amsterdam, The Netherlands
Clin Infect Dis 43:357-64. 2006
..Oral miltefosine has been proven to be safe and effective in the treatment of Indian VL but has not been studied in Africa or in persons with HIV and VL coinfection...
- Utility of lymph node aspiration in the diagnosis of visceral leishmaniasis in Sudan
Zahir O E Babiker
Medecins Sans Frontieres Holland, Amsterdam, The Netherlands
Am J Trop Med Hyg 76:689-93. 2007
..Lymph node and splenic aspirations were similarly accurate as tests of cure after treatment of 50 VL patients in southern Sudan. Pre-treatment LNA results were negative in 20 cases of severe post kala-azar dermal leishmaniasis...
- Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome
Rachel Ter Horst
Medecins Sans Frontieres, Amsterdam, The Netherlands
Clin Infect Dis 46:1702-9. 2008
..Coinfection with human immunodeficiency virus (HIV) and Leishmania donovani visceral leishmaniasis (VL) in Africa is an emerging, poorly understood disease...
- Unresponsiveness to AmBisome in some Sudanese patients with kala-azar
Marius Mueller
Medecins Sans Frontieres, Plantage Middenlaan 14, 1018 DD Amsterdam, The Netherlands
Trans R Soc Trop Med Hyg 101:19-24. 2007
..002) and underlying immunosuppressive disease: tuberculosis (three cases) or HIV (two cases). Because AmBisome monotherapy may fail in Sudan, a combination of AmBisome and SSG is recommended for relapse cases...
Visceral leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of risk factors and trendsStanislaw Gorski
Medecins Sans Frontieres, Amsterdam, The Netherlands
PLoS Negl Trop Dis 4:e705. 2010
..Risk factors associated with L. donovani visceral leishmaniasis (VL; kala azar) relapse are poorly characterized...
- Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy
Yosef Melaku
Medecins Sans Frontieres Holland, Amsterdam, The Netherlands
Am J Trop Med Hyg 77:89-94. 2007
..22, 95% CI = 0.10-0.50) in 2003, and 86% lower (OR = 0.14, 95% CI = 0.07-0.27) in 2004-2005. In remote field settings, 17 days of SSG combined with PM gives better survival and initial cure rates than 30 days of SSG monotherapy...
- Evaluation of a mass distribution programme for fine-mesh impregnated bednets against visceral leishmaniasis in eastern Sudan
Koert Ritmeijer
Medecins Sans Frontieres Holland, Amsterdam, The Netherlands
Trop Med Int Health 12:404-14. 2007
..The effectiveness of ITN depends on behavioural factors, which differ between communities...
- Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan
Hans Veeken
Medecins Sans Frontieres Holland, Amsterdam, The Netherlands
Trop Med Int Health 8:164-7. 2003
..The rK39 dipstick is a good screening test for kala-azar; but further development is required before it can replace the DAT as a diagnostic test in endemic areas of the Sudan...
- Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan
Simon Collin
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
Clin Infect Dis 38:612-9. 2004
..7), and splenomegaly (OR, 2.9). A higher risk of death was associated with episodes of diarrhea (OR, 1.4), vomiting (OR, 2.7), and bleeding (OR, 2.9). Relapse and PKDL occurred in 3.9% and 10.0% of cases, respectively...
- A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan
Marius Mueller
, 67-74 Saffron Hill, London EC1N 8QX, UK
J Antimicrob Chemother 58:811-5. 2006
..CONCLUSIONS: AmBisome treatment for VL appears to be safe and effective for pregnant women and their foetuses. We recommend the use of AmBisome as first-line treatment for these patients...
- Liposomal amphotericin B for the treatment of visceral leishmaniasis
Caryn Bern
Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Clin Infect Dis 43:917-24. 2006
..The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs...
- Unseen Kala-azar deaths in south Sudan (1999-2002)
Simon M Collin
Department of Infectious and Tropical Diseases, Infectious Disease Unit, London School of Hygiene and Tropical Medicine, London, UK
Trop Med Int Health 11:509-12. 2006
..To estimate the number of deaths due to primary or relapse kala-azar (KA), which occurred unseen within the catchment area of Médecins Sans Frontières (MSF) clinics in southern Sudan...
- Treating HIV/AIDS and leishmaniasis coinfection in Ethiopia
Aranka Anema
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC
CMAJ 172:1434-5. 2005
